公开(公告)号：US20100159486A1

公开(公告)日：2010-06-24

申请号：US12513032

申请日：2007-11-01

申请人： Lance A. Liotta ,  Wediong Zhou ,  Wolff Kirsch ,  Virginia Espina ,  Emanuel Petricoin, III ,  Mark Ross ,  Claudius Mueller ,  Shino Magaki

发明人： Lance A. Liotta ,  Wediong Zhou ,  Wolff Kirsch ,  Virginia Espina ,  Emanuel Petricoin, III ,  Mark Ross ,  Claudius Mueller ,  Shino Magaki

IPC分类号： G01N33/53 ,  C12Q1/02 ,  G01N33/566 ,  G01N33/00 ,  C07K16/18

CPC分类号： G01N33/6896 ,  G01N2800/2821 ,  G01N2800/2871

摘要： Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.

摘要翻译： 已经发现了低分子量（LMW）肽，其指示诸如阿尔茨海默氏病（AD），认知障碍和脑微血管损伤之类的神经病学状况。 评估患者样本中存在这样的LMW肽是检测神经系统疾病和监测疾病进展的有效手段。 LMW肽特别可用于在早期阶段检测神经系统疾病而无侵入性手术。

公开(公告)号：US20050043593A9

公开(公告)日：2005-02-24

申请号：US09906661

申请日：2001-07-18

申请人： Ben Hitt ,  Emanuel Petricoin III ,  Peter Levine ,  Lance Liotta

发明人： Ben Hitt ,  Emanuel Petricoin III ,  Peter Levine ,  Lance Liotta

IPC分类号： G01N27/62 ,  G01N33/48 ,  G06F19/00 ,  G01N33/50 ,  C12Q1/68 ,  A61B5/00

CPC分类号： G06F19/24 ,  G06F19/00 ,  G06F19/20 ,  G16H10/40 ,  G16H50/70 ,  Y10S707/99933 ,  Y10S707/99943

摘要： The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e.g., a biological sample from a human, e.g., serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate.), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e.g., patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.

公开(公告)号：US20110318336A1

公开(公告)日：2011-12-29

申请号：US13075163

申请日：2011-03-29

申请人： Emanuel Petricoin, III ,  Julia Wulfkuhle ,  Angela Zupa

发明人： Emanuel Petricoin, III ,  Julia Wulfkuhle ,  Angela Zupa

IPC分类号： A61K39/395 ,  A61K31/517 ,  A61P35/00 ,  A61K31/506 ,  A61K31/404 ,  C40B40/10 ,  C40B30/04 ,  A61K31/5377

CPC分类号： G01N33/6884 ,  A61K31/00 ,  G01N33/57423 ,  G01N2800/02

摘要： This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients.

摘要翻译： 本发明涉及患者侵袭性肺癌肿瘤的鉴别和治疗。 更具体地，其提供了鉴定具有侵袭性淋巴结阴性（N0）肿瘤和总生存差的可能性的非小细胞肺癌（NSCLC）患者的方法。 该方法包括确定某些鉴定的蛋白质中的一种或多种是否在从患者肿瘤获得的肿瘤细胞中被活化的步骤，其中一种或多种蛋白质的活化指示患者具有侵略性的N0肿瘤并且可能具有 总体生存差 本发明还提供了用于选择具有N0肿瘤的NSCLC患者的治疗方法和用于治疗这种患者的方法。 它进一步提供了一种用于鉴定具有侵袭性N0肿瘤的NSCLC患者和总体存活差的可能性的试剂盒和用于治疗这种患者的药物组合物。

公开(公告)号：US20130344062A1

公开(公告)日：2013-12-26

申请号：US13841749

申请日：2013-03-15

申请人： Emanuel Petricoin, III ,  Julia Wulfkuhle ,  Angela Zupa

发明人： Emanuel Petricoin, III ,  Julia Wulfkuhle ,  Angela Zupa

IPC分类号： G01N33/68

CPC分类号： G01N33/6884 ,  A61K31/00 ,  G01N33/57423 ,  G01N2800/02

摘要： This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients.

摘要翻译： 本发明涉及患者侵袭性肺癌肿瘤的鉴别和治疗。 更具体地，其提供了鉴定具有侵袭性淋巴结阴性（N0）肿瘤和总生存差的可能性的非小细胞肺癌（NSCLC）患者的方法。 该方法包括确定某些鉴定的蛋白质中的一种或多种是否在从患者肿瘤获得的肿瘤细胞中被活化的步骤，其中一种或多种蛋白质的活化指示患者具有侵略性的N0肿瘤并且可能具有 总体生存差 本发明还提供了用于选择具有N0肿瘤的NSCLC患者的治疗方法和用于治疗这种患者的方法。 它进一步提供了一种用于鉴定具有侵袭性N0肿瘤的NSCLC患者和总体存活差的可能性的试剂盒和用于治疗这种患者的药物组合物。

公开(公告)号：US20120321615A1

公开(公告)日：2012-12-20

申请号：US13481629

申请日：2012-05-25

申请人： Emanuel Petricoin, III ,  Lance A. Liotta ,  Mariaelena Pierobon ,  Valerie Calvert

发明人： Emanuel Petricoin, III ,  Lance A. Liotta ,  Mariaelena Pierobon ,  Valerie Calvert

IPC分类号： C40B30/04 ,  G01N33/574 ,  A61K31/519 ,  A61K31/4545 ,  A61K31/506 ,  A61P35/04 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K33/40 ,  A61K31/365 ,  A61K31/415 ,  C40B40/10 ,  A61K31/404

CPC分类号： G01N33/57419 ,  C12Q1/485 ,  G01N2333/90245

摘要： Disclosed herein is a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation of one or more of certain proteins compared to a positive and/or negative reference standard; or the total amount of COX-2 protein compared to a positive and/or negative reference standard. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing the methods of the invention.

摘要翻译： 本文公开了一种用于预测具有结肠直肠癌的受试者的预后，转移的可能性或对其进行侵袭性治疗的可取性的方法，其包括在来自受试者的样品中测定一种或多种受试者的磷酸化水平 某些蛋白质与正和/或负参考标准相比; 或与正和/或负参考标准相比的COX-2蛋白的总量。 还描述了用于治疗可能产生转移性结直肠癌的受试者的方法，以及用于实施本发明的方法的药物组合物和试剂盒。

公开(公告)号：US20100298157A1

公开(公告)日：2010-11-25

申请号：US12600755

申请日：2008-05-19

申请人： Emanuel Petricoin, III ,  Valerie Calvert ,  Zobair Younossi ,  Lance Liotta

发明人： Emanuel Petricoin, III ,  Valerie Calvert ,  Zobair Younossi ,  Lance Liotta

IPC分类号： C40B30/04

CPC分类号： G01N33/6872 ,  G01N2800/042 ,  G01N2800/52

摘要： A subject's likelihood of responding to bariatric surgery can be assessed by measuring the phosphorylation state of certain proteins found in white adipose tissue (WAT). In particular, measuring the phosphorylation state of particular proteins can predict a patient's likelihood of resolving diabetes mellitus following bariatric surgery. In addition, evaluating the phosphorylation state of certain proteins forecasts a patient's capacity to reduce excess body weight and/or waist size following bariatric surgery. Such tests are valuable tools for managing the diseases of diabetes and obesity and determining who would most likely benefit from bariatric surgical procedures such as gastic bypass surgery.

摘要翻译： 受试者应对肥胖手术的可能性可以通过测量在白色脂肪组织（WAT）中发现的某些蛋白质的磷酸化状态来评估。 特别地，测量特定蛋白质的磷酸化状态可以预测患者在减肥手术后解决糖尿病的可能性。 此外，评估某些蛋白质的磷酸化状态可预测患者在减肥手术后减少体重和/或腰围的能力。 这些测试是管理糖尿病和肥胖疾病的重要工具，并确定哪些人最有可能从减肥手术中获益，如手术旁路手术。